Health · Medical Research · 15 hrs ago
Early trial finds ERAS-0015 safe and shrinks some lung and pancreatic tumors
The AURORAS-1 Phase I trial tested ERAS-0015, an anticancer drug, in people with cancer.
The study focused on hard-to-treat diseases, including lung and pancreatic cancer.
Results showed that the drug was safe in the trial.
It also caused some tumors to shrink in patients.
These findings are an early result from a Phase I study, rather than evidence that the drug cures these cancers.
The results may matter because both cancers can be difficult to treat.
The source gives no details about next steps for the drug or trial.
Results from the AURORAS-1 Phase I trial found that the anticancer drug ERAS-0015 was safe.
The trial results also showed that tumors shrank in some cases.
The reported cancers included hard-to-treat lung and pancreatic cancers.
Medical Xpress published the report on November 20, 2026.
- Who
- The AURORAS-1 trial tested the drug ERAS-0015.
- What
- Phase I results showed the drug was safe and caused some tumors to shrink.
- When
- The results were reported on November 20, 2026.
- Where
- Not stated.
- Why
- The drug is an anticancer treatment for hard-to-treat diseases such as lung and pancreatic cancer.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Trial
- AURORAS-1
- Trial phase
- Phase I
- Drug
- ERAS-0015
- Cancers
- Lung and pancreatic
- Report date
- November 20, 2026